Ubiquitin C-Terminal Hydrolase L1

UCH-L1 (also known as PGP9.5 or PARK5) is one of the most abundant proteins in neurons, where it plays a critical role in the ubiquitin-proteasome system — the cellular machinery responsible for tagging and degrading damaged or unnecessary proteins. Under normal conditions, UCH-L1 is contained within intact neurons and is essentially absent from the bloodstream. Following traumatic brain injury, stroke, or other forms of neuronal damage, UCH-L1 is released through disrupted cell membranes and enters the circulation, where it can be detected by immunoassay within hours of injury.

UCH-L1 and GFAP were co-developed as a paired biomarker panel for the evaluation of mild traumatic brain injury. While GFAP reflects astrocytic (glial) damage and may indicate structural brain lesions, UCH-L1 reflects neuronal cell body injury and may capture injury patterns that do not involve significant astrocytic disruption. The combination provides complementary information: GFAP demonstrates higher specificity for intracranial hemorrhage and mass lesions visible on CT, while UCH-L1 may detect neuronal injury even in the absence of imaging-visible pathology.

UCH-L1 rises rapidly after brain injury — often within the first few hours — and has a relatively short half-life, meaning that its detection window is narrower than that of GFAP. Blood levels typically peak within 8 hours of injury and may return toward baseline within 48 hours. This rapid kinetic profile makes UCH-L1 particularly useful for early assessment but may limit its utility for delayed presentations unless combined with longer-lasting markers.

Prevena Health is exploring whether continuous UCH-L1 monitoring may help capture the narrow detection window of this rapid-rising neuronal biomarker. Because UCH-L1 peaks within hours and may decline within 48 hours, delayed testing risks missing elevated levels entirely. A wearable biosensor platform capable of detecting UCH-L1 in real time may support immediate identification of neuronal injury events, particularly for at-risk populations who may not immediately present to emergency departments.

This approach aims to complement the established GFAP/UCH-L1 paired panel by adding temporal resolution. In research settings involving contact sports, military training, or fall-risk elderly populations, continuous monitoring may capture injury-related UCH-L1 spikes that would otherwise go undetected between clinical assessments, potentially supporting a more complete understanding of cumulative neuronal injury.